Cancer Pain - Pipeline Review, H2 2014


#227630

146pages

Global Markets Direct

$ 2000

In Stock

Cancer Pain - Pipeline Review, H2 2014

Summary

Global Markets Directs, Cancer Pain - Pipeline Review, H2 2014, provides an overview of the Cancer Pains therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cancer Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cancer Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Cancer Pain Overview 11
Therapeutics Development 12
Pipeline Products for Cancer Pain - Overview 12
Pipeline Products for Cancer Pain - Comparative Analysis 13
Cancer Pain - Therapeutics under Development by Companies 14
Cancer Pain - Therapeutics under Investigation by Universities/Institutes 17
Cancer Pain - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Cancer Pain - Products under Development by Companies 21
Cancer Pain - Products under Investigation by Universities/Institutes 23
Cancer Pain - Companies Involved in Therapeutics Development 24
Amgen Inc. 24
AstraZeneca PLC 25
BioDelivery Sciences International, Inc. 26
Nektar Therapeutics 27
Daiichi Sankyo Company, Limited 28
Egalet Corporation 29
Aphios Corporation 30
Nippon Kayaku Co., Ltd. 31
Nippon Shinyaku Co., Ltd. 32
Orion Oyj 33
Pfizer Inc. 34
Zeria Pharmaceutical Co Ltd 35
GW Pharmaceuticals plc 36
IntelGenx Corp. 37
Benitec Biopharma Limited 38
Kolon Life Science, Inc. 39
Teikoku Seiyaku Co., Ltd. 40
Aoxing Pharmaceutical Company, Inc 41
BCN Peptides, S.A. 42
Grunenthal GmbH 43
AngioChem Inc. 44
WEX Pharmaceuticals Inc. 45
Virobay Inc. 46
Dimerix Bioscience Pty Ltd 47
Winston Pharmaceuticals, Inc. 48
Encore Therapeutics Inc. 49
Sorrento Therapeutics, Inc. 50
Afferent Pharmaceuticals, Inc. 51
ChironWells GmbH 52
Northern Light Pharmaceuticals AB 53
Cancer Pain - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 59
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
fentanyl citrate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
tramadol hydrochloride SR - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
tilidine hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
nabiximols - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Tetrodotoxin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
cebranopadol - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
morphine sulfate ER - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
TK-641 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
tapentadol hydrochloride ER - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
methadone hydrochloride - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
hydromorphone hydrochloride - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
tanezumab - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
saracatinib - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
fulranumab - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
dexmedetomidine hydrochloride - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
fentanyl citrate - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
PGN-202 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
fentanyl citrate SR - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
resiniferatoxin - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
DD-04107 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
dronabinol - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
VBY-825 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
zucapsaicin - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ANG-2002 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Z-360 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Nervarna - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
NKTR-192 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
buprenorphine hydrochloride ER - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
AF-353 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
INT-0028 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
HS-198 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
QX-314 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
calpastatin - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Small Molecule to Antagonize Chemokine Receptor for Cancer Pain - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
KLS-2010 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
ZEP-3 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
BBI-11008 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
ketamine hydrochloride ER - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
DMX-200 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Cancer Pain - Recent Pipeline Updates 124
Cancer Pain - Dormant Projects 137
Cancer Pain - Discontinued Products 138
Cancer Pain - Product Development Milestones 139
Featured News & Press Releases 139
Sep 10, 2014: Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting 139
Sep 03, 2014: Rexahn Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Novel Targeted Cancer Drug Delivery Platform 139
Aug 26, 2014: Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen 139
Jul 16, 2014: Prima Receives US Patent Grant for CVac 141
Apr 28, 2014: Hospira Files Petition Against Aurobindo Over Patent Infringement 142
Apr 28, 2014: GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain 142
Feb 18, 2014: Preclinical Data on Angiochem Pain Program Published in Journal of Clinical Investigation 143
Feb 10, 2014: Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq to Include Australia, Canada and Mexico 143
Dec 05, 2013: Orion settles patent dispute over the proprietary drug Precedex 144
Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan 144
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 146
Disclaimer 146

List of Tables
Number of Products under Development for Cancer Pain, H2 2014 12
Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 23
Cancer Pain - Pipeline by Amgen Inc., H2 2014 24
Cancer Pain - Pipeline by AstraZeneca PLC, H2 2014 25
Cancer Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2014 26
Cancer Pain - Pipeline by Nektar Therapeutics, H2 2014 27
Cancer Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 28
Cancer Pain - Pipeline by Egalet Corporation, H2 2014 29
Cancer Pain - Pipeline by Aphios Corporation, H2 2014 30
Cancer Pain - Pipeline by Nippon Kayaku Co., Ltd., H2 2014 31
Cancer Pain - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 32
Cancer Pain - Pipeline by Orion Oyj, H2 2014 33
Cancer Pain - Pipeline by Pfizer Inc., H2 2014 34
Cancer Pain - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2014 35
Cancer Pain - Pipeline by GW Pharmaceuticals plc, H2 2014 36
Cancer Pain - Pipeline by IntelGenx Corp., H2 2014 37
Cancer Pain - Pipeline by Benitec Biopharma Limited, H2 2014 38
Cancer Pain - Pipeline by Kolon Life Science, Inc., H2 2014 39
Cancer Pain - Pipeline by Teikoku Seiyaku Co., Ltd., H2 2014 40
Cancer Pain - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2014 41
Cancer Pain - Pipeline by BCN Peptides, S.A., H2 2014 42
Cancer Pain - Pipeline by Grunenthal GmbH, H2 2014 43
Cancer Pain - Pipeline by AngioChem Inc., H2 2014 44
Cancer Pain - Pipeline by WEX Pharmaceuticals Inc., H2 2014 45
Cancer Pain - Pipeline by Virobay Inc., H2 2014 46
Cancer Pain - Pipeline by Dimerix Bioscience Pty Ltd, H2 2014 47
Cancer Pain - Pipeline by Winston Pharmaceuticals, Inc., H2 2014 48
Cancer Pain - Pipeline by Encore Therapeutics Inc., H2 2014 49
Cancer Pain - Pipeline by Sorrento Therapeutics, Inc., H2 2014 50
Cancer Pain - Pipeline by Afferent Pharmaceuticals, Inc., H2 2014 51
Cancer Pain - Pipeline by ChironWells GmbH, H2 2014 52
Cancer Pain - Pipeline by Northern Light Pharmaceuticals AB, H2 2014 53
Assessment by Monotherapy Products, H2 2014 54
Number of Products by Stage and Target, H2 2014 57
Number of Products by Stage and Mechanism of Action, H2 2014 61
Number of Products by Stage and Route of Administration, H2 2014 64
Number of Products by Stage and Molecule Type, H2 2014 66
Cancer Pain Therapeutics - Recent Pipeline Updates, H2 2014 124
Cancer Pain - Dormant Projects, H2 2014 137
Cancer Pain - Discontinued Products, H2 2014 138

List of Figures
Number of Products under Development for Cancer Pain, H2 2014 12
Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Products, H2 2014 20
Assessment by Monotherapy Products, H2 2014 54
Number of Products by Top 10 Target, H2 2014 55
Number of Products by Stage and Top 10 Target, H2 2014 56
Number of Products by Top 10 Mechanism of Action, H2 2014 59
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 60
Number of Products by Top 10 Route of Administration, H2 2014 63
Number of Products by Stage and Top 10 Route of Administration, H2 2014 64
Number of Products by Top 10 Molecule Type, H2 2014 65
Number of Products by Stage and Top 10 Molecule Type, H2 2014 66